The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal radiotherapy pattern.

Trial Details

NCT ID

NCT05798845

Phase

PHASE2

Sponsor

Shanghai Chest Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

SBRT+LDRT
Toripalimab
Chemotherapy drug

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Age 18 to 75 years old, gender is not limited.
ECOG performance status 0-1.
non-small cell lung cancer diagnosed by pathology.
sufficient tumor tissue available for biomarker analysis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →